News - Affymax

Filter

Current filters:

Affymax

Popular Filters

Takeda to withdraw NDA as Omontys pact with Affymax ends

Takeda to withdraw NDA as Omontys pact with Affymax ends

15-06-2014

USA-based Affymax and Japan's Takeda Pharmaceutical revealed on Friday that they have terminated their…

AffymaxBiotechnologyLicensingOmontysOncologyRegulationTakeda Pharmaceutical

Affymax slashes workforce following Omontys problems; evaluating options

19-03-2013

US biopharma company Affymax (Nasdaq: AFFY) says that it will reduce its workforce as part of a plan…

AffymaxBiotechnologyFinancialManagementOmontysOncologyPharmaceutical

Takeda and Affymax recall all lots of anemia drug Omontys

25-02-2013

US drugmaker Affymax (Nasdaq: AFFY) and its licensee, Japan's Takeda Pharmaceutical (TYO: 4502), said…

AffymaxMarkets & MarketingNorth AmericaOmontysPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda and Affymax in supply deal for Omontys injection with US Renal Care

10-08-2012

Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) and Affymax (Nasdaq: AFFY) have said that…

AffymaxMarkets & MarketingNephrology and HepatologyNorth AmericaOmontysPharmaceuticalTakeda Pharmaceuticals

FDA backs Affymax and Takeda drug Omontys for anemia due to CKD

28-03-2012

The US Food and Drug Administration yesterday approved Omontys (peginesatide, formerly known as Hematide)…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontyspeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Takeda to drop peginesatide commercialization in Japan

19-12-2011

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has decided not to commercialize peginesatide…

AffymaxAsia-PacificLicensingNephrology and HepatologypeginesatidePharmaceuticalTakeda Pharmaceuticals

FDA committee backs Affymax CKD drug

09-12-2011

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

US FDA sets PDUFA action dates for Bydureon and peginesatide

12-08-2011

US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Affymax gets $10 million milestone from Takeda on peginesatide NDA acceptance

11-08-2011

California, USA-based Affymax (Nasdaq: AFFY) says it has received a $10 million development milestone…

AffymaxFinancialHematideOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top